New SIK3 Inhibitor Approved For Autoimmune Disease Trial
Belgium has approved a first‑in‑human study of Onco3R Therapeutics’ SIK3‑selective inhibitor O3R‑5671, clearing a single‑ and multiple‑ascending dose trial...
New Meta-Analysis: GeneSight Test Improves Depression Outcomes
Across six prospective controlled studies totaling 3,532 adults with major depressive disorder and at least one prior treatment failure,...
Roivant Unveils Remarkable Graves’ Disease Remission Data
In a small proof-of-concept study of uncontrolled Graves’ disease, approximately 80% (17/21) of patients who completed a six-month off-treatment...
Successful ART27.13 Phase 2 Data Soars Partnering Outlook
Interim data from the Phase 2 CAReS trial reported improvements in body weight, lean body mass, and activity among...
Successful EndoQuest Paradigm Trial Procedure at AdventHealth
EndoQuest’s multicenter PARADIGM trial has moved beyond its first site, with AdventHealth Orlando completing its first colorectal endoscopic submucosal...
Artelo’s Cancer Drug Shows Promise in Phase 2 CARES Trial
Artelo’s interim Phase 2 readout in cancer anorexia-cachexia syndrome (CACS) shows patients titrated to 1300 micrograms of ART27.13 gained...
Pharma’s Next Opportunity: AI and Standardization
At Veeva R&D and Quality Summit in Boston, the pain points of managing complex processes and entering data manually...
Ascendis to Share New Rare Disease Endocrinology Data
Ascendis is set to present 52-week pivotal data linking improvements in lower extremity alignment to gains in physical functioning...
New Hope: Alpha Tau Treats First Pancreatic Cancer Patient
Alpha Tau has treated the first patient in IMPACT, a U.S. multi-center pilot evaluating intratumoral Alpha DaRT in combination...
Neuro Tech Triumph: Vielight Powers Sports Champions
Season-long analyses in collegiate football athletes reported decreases in diffusion MRI markers associated with neuroinflammation among players using Vielight’s...